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Objectives. To assess perioperative outcomes and blood pressure (BP) responses to an implantable carotid sinus baroreflex
activating system being investigated for the treatment of resistant hypertension.
Methods. We report on the first seventeen patients enrolled in a multicenter study . Bilateral perivascular carotid sinus
electrodes (CSL) and a pulse generator (IPG) are permanently implanted. Optimal placement of the CSL is determined by
intraoperative BP responses to test activations. Acute BP responses were tested postoperatively and during the first four
months of follow-up.
Results. Prior to implant, BP was 189.6 27.5/110.7 15.3 mmHg despite stable therapy (5.2 1.8 antihypertensive
drugs). The mean procedure time was 202 43 minutes. No perioperative strokes or deaths occurred. System tests
performed 1 or up to 3 days postoperatively resulted in significant (all p 0.0001) mean maximum reduction, with stan-
dard deviations and 95% confidence limits for systolic BP, diastolic BP and heart rate of 28 22 (17, 39) mmHg, 16 11
(10, 22) mmHg and 8 4 (6, 11) BPM, respectively. Repeated testing during 3 months of therapeutic electrical activation
demonstrated a durable response.
Conclusions. These preliminary data suggest an acceptable safety of the procedure with a low rate of adverse events and
support further clinical development of baroreflex activation as a new concept to treat resistant hypertension.
Keywords: Hypertension; Surgery; Baroreflex; Carotid sinus; Medical device; Autonomic nervous system.Introduction
The role of vascular surgeons in the treatment of arte-
rial hypertension is usually restricted to the correction
of secondary causes of hypertension, such as repair of
renal artery stenosis, or resection of pheochromocy-
toma and aldosterone-producing adenomas. Many
other vascular procedures treat the sequelae of athero-
sclerosis in patients with longstanding uncontrolled
arterial hypertension. Even with advances in medical
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patients fail to reach their goal blood pressure due
to refractoriness to multi-drug treatment or poor com-
pliance.1e8 In such patients, new treatment options
are needed to reduce hypertension induced cardio-
vascular morbidity.9,10
A key mechanism of blood pressure control,
recently re-evaluated as a potential therapeutic, ap-
proach is the electrical activation of the carotid baro-
reflex. In the 1960s and 1970s the carotid baroreflex
was modulated as part of the treatment of resistant
hypertension and refractory angina pectoris. The ca-
rotid sinus nerves were chronically stimulated using
implanted nerve electrodes and an implantable radio-
frequency controlled receiver.11e17 This technique
never became established as a viable therapy forved.
415An Implantable Carotid Sinus Baroreflex Activating Systemhypertension. This was partially due to the
simultaneous development of new agents used in
the treatment of hypertension (e.g. Minoxidil and
ACE-Inhibitors) and technical limitations of implant-
able medical devices of that era, e.g. stimulation of
tissues adjacent to the carotid sinus nerves causing
pain in patients equipped with the device and poor
energy transmission properties since the device was
not fully implantable. These earlier and more recent
observations from data in chronically instrumented
animals, demonstrate that the carotid baroreflex can
influence the long-term regulation of arterial blood
pressure.18e23
A new implantable active medical device, (Rheos,
CVRx. Inc., Maple Grove, MN, USA) activates the
carotid baroreflex through electrical stimulation of
the carotid sinus wall: Electrodes implanted on the
exterior surface of the carotid sinus wall are connected
to a battery powered impulse generator (IPG). This
concept was initially validated in animal studies,21e23
and subsequently in patients undergoing elective
carotid surgery in which acute unilateral electrical
stimulation of the carotid sinus wall reduced blood
pressure and heart rate. These hemodynamic effects
increased gradually as the amplitude (voltage) of stim-
ulation was increased in a stepwise manner.24
For an early assessment of perioperative outcomes
and blood pressure (BP) responses we now report the
perioperative data from the first 17 patients with drug
resistant hypertension enrolled in a European multi-
center feasibility study.25 The study protocol hypothe-
sizes that chronic electrical stimulation of the carotid
sinus wall added to stable maximal drug therapy
will result in sustained reductions of systolic blood
pressure of at least 10 mmHg with an acceptable
risk benefit ratio.
This preliminary analysis focuses on our early
experience and perioperative outcomes and details
of the surgical procedure. As such it does not allow
full statistical analysis of the prospectively defined
primary and secondary outcome variables as planned
for the complete trial.
Methods
Study and study criteria
The study is currently conducted in 6 clinical centers in
Europe. It was approved by the institutional review
board at each participating center, and all patients pro-
vided written informed consent before the start of
the study. The main eligibility criteria are given in
Table 1. Patients who fulfill these criteria are enrolledinto a prospective, non-randomized, self-controlled
registry of safety and efficacy of blood pressure reduc-
tion. To facilitate this assessment the patient’s antihy-
pertensive regimen is held constant during the first
four months of the study unless doing so would com-
promise patient safety. Per protocol, the first three
patients are to be excluded from efficacy and safety
analyses and will only be individually summarized in
the final study report. The formal primary endpoints
of the study are to be analysed at 4 month follow-up,
i.e. after 3 months of continued electrical baroreflex ac-
tivation therapy. For safety, all adverse events are eval-
uated and the device and procedure related adverse
events rate is estimated. For efficacy, the trial hypothe-
sis calls for a reduction in systolic (office-cuff) blood
pressure of at least 10 mmHg at that timepoint. A total
of 50 patients are to be enrolled in order to yield at least
45 evaluable patients for the primary endpoints.
Device and surgical technique
The active implantable device
The implantable Baroreflex Hypertension Therapy
(BHT) system consists of bilateral Carotid Sinus Leads
(CSL) and a battery powered, programmable active
IPG. Biocompatible materials are used on all surfaces
The CSL conducts the activation energy from the IPG
to stimulate the baroreceptor fibers in the vessel walls
of both carotid sinuses. These impulses are transmit-
ted to the brainstem, where the increased nerve traffic
originating from baroreceptor afferents is interpreted
as an elevated blood pressure and results in central
nervous system modulation of sympathetic and vagal
outflows which reduce blood pressure and heart rate.
This device is fully programmable by an external
system, linked telemetrically to the IPG and allows
the physician to non-invasively adjust the stimulation
parameters delivered to the CSL. The patient can tem-
porarily disable or turn off the IPG, respectively by
using a magnet or a Patient Wand. Stimulation im-
pulses can be delivered to one or both CSLs. The
range of the main programmable electrical parameters
is given in Table 2.
Table 1. Main Inclusion/Exclusion Criteria
Age: 20 yrs
Bilateral carotid bifurcations located at or below C3eC4
No Carotid Stenosis> 50%
No prior surgery or radiation in the carotid sinus region
Drug resistant Hypertension (not secondary to a treatable cause)
And SBP 160 mmHg and/or DBP 90 mmHg despite adhering
to two months of stable full therapy with at least three anti-
hypertensive medications, of which at least one must be a diuretic.Eur J Vasc Endovasc Surg Vol 33, April 2007
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device activation
Electrical parameters can be separately adjusted for
each of the two CSLs (left and right) in order to adapt
to potential differences in stimulation thresholds and
hemodynamic responses.
The standard settings for testing the blood pressure
response at least once postoperatively at pre-
discharge and at every follow-up visit are the follow-
ing: Continuous bilateral stimulation with a frequency
of 100 Hz and an impulse width of 480 ms. Stimulus
amplitude (V¼Voltage) is increased in steps of 1 V
from 1e6 V, each for 5 minutes. Acute changes in
office cuff blood pressure and pulse rate are measured
with an automated device.
During these tests the patient is allowed to rest qui-
etly. The postoperative and 1-Month follow-up tests
were performed prior to the initiation of chronic ther-
apy. For subsequent tests during BHT, the device was
turned off for 5 to 30 minutes before any acute testing.
Additional acute tests are regularly done with other
frequencies and impulse widths at the follow-up
visits to further explore how each patient responds
to BHT. Therapy is programmed individually for
each patient taking into account results of their office
blood pressure, 24-hour ambulatory blood pressure,
when available, and responses to acute tests.
Preparation for surgery
On the day of surgery morning doses of antihyperten-
sive medications were held, except for beta-adrenergic
blockers and aspirin was given unless otherwise con-
traindicated. An infusion of sodium nitroprusside, or
nitroglycerine, was used to control blood pressure
preoperatively and all other antihypertensive medica-
tions were administered in the immediate postopera-
tive period. All procedures were performed under
general anesthesia. It is critical to the conduct of the
procedure that agents which blunt the baroreflex be
avoided, as has been briefly communicated previ-
ously,26 and thus will not be expanded upon at this
time. The level of the carotid bifurcation was marked
on each side using ultrasound guidance. A catheter
was placed in the nondominant radial artery for con-
tinuous monitoring of the patients blood pressure.
Table 2. IPG Stimulation Parameters
Sequence of Stimuli Frequency
(Hz)
Amplitude
(V)
Impulse
Duration (ms)
Continuous stimuli
or bursts of variable
duration
10e100 1e7.5
(in steps
of 0.5 V)
120e760Eur J Vasc Endovasc Surg Vol 33, April 2007Access to the carotid sinus
The patient was positioned and the surgical field pre-
pared which allowed access for three incisions, one
over each carotid bifurcation and a third inferior to
the clavicle for the IPG. A transverse or vertical was
made at the level of the bifurcation, at the discretion
of the attending surgeon. The incision was deepened
and the common carotid artery was exposed accord-
ing to the standard practice of the surgeon. The vagus
nerve was identified and protected. The carotid dis-
section was extended cephalad exposing the bifur-
cation. In this process the Ansa cervicalis may be
divided, however, all other nerves including the
hypoglossal which was mobilized if needed, were
preserved. The carotid artery bifurcation was then
mobilized circumferentially, however, dissection within
the bifurcation was avoided so as to minimize the risk
of injury to the neurovascular bundle. If the geometry
of the carotid bifurcation was such that the angle be-
tween the internal and external carotid arteries was
great and the arteries separate rapidly, the internal ca-
rotid artery was dissected circumferentially two centi-
meters above the flow divider to facilitate fixation of
the electrode around the sinus without directly dis-
secting near the flow divider of the carotid bifurcation
where the carotid sinus nerve was most likely to be
located.
Carotid sinus lead application and testing
At this time patients receiving inhalational agents, as
part of their anesthetic regimen, had the agents re-
duced, or temporarily discontinued, and supplemen-
tal narcotics, barbiturates and/or benzodiazepines
administered intravenously to maintain adequate
anesthesia.
The electrode was positioned on the bifurcation in
the area of the carotid sinus. If the carotid sinus was
clearly seen the electrode is applied with the active
area centeredon the sinus. If the sinuswasnot adiscrete
structure the lead is positioned around the carotid
bifurcation so that the active area was centered on the
internal carotid artery at a point opposite the neurovas-
cular bundle within the bifurcation. The electrode was
positioned on the distal fivemillimeters of the common
carotid artery extending cephalad onto the bifurcation.
The electrode was then tested to assess the hemody-
namic response. The electrode was then repositioned
in the cephalad-caudal orientation as well as being ro-
tated around the long axis of the carotid artery until
the location providing the optimal hemodynamic re-
sponse was identified. Several locations were tested
to assure that the position producing the optimal re-
sponse was identified. During testing the electrode
and lead were connected to the IPG and briefly
417An Implantable Carotid Sinus Baroreflex Activating Systemactivated with impulses of 3 V, 100 Hz and a pulse
width of 480 ms once blood pressure and heart rhythm
were stable and not influenced bymechanical manipu-
lation.Within 1minute, stimulation using these param-
eters at a correct location should reduce systolic blood
pressure by at least 10e20 mmHg and heart rate by
5e10 beats/minute.Once the optimal locationwas con-
firmed the electrodewas sutured in place (6-Opolypro-
phylene; Prolene). Thedesign of the electrode allowed
all suturing to be performed on the superficial aspect of
the artery and for sutures to be placed on the common
and external carotid arteries avoiding direct suturing
to the carotid sinus thus reducing the risk of injury to
these structures. The procedure was then repeated
on the contralateral side.
Lead tunneling procedure and IPG implantation
After confirming lead position and appropriate elec-
trode function the level of anesthesia was deepened
to allow tunneling of the lead bodies. This was accom-
plished by administering inhalational agents or
intravenous narcotics or benzodiazepines. Next a sub-
cutaneous pocket was made inferior to the clavicle for
the IPG (IPG pocket). A tunnel was created from the
cervical incision ipsilateral to the IPG pocket to
the space between the sternal and clavicular heads of
the sternocleidomastoid muscle (SCM). This was be-
tween the vessels and the SCM and was large enough
to allow the index finger to be is inserted from above
down to the fascial layer between the heads of the
SCM. A tunnel was fashioned from the IPG pocket up
to the space between the heads of the SCM which was
then opened from below by spreading a clamp on the
tip of the index finger thus protecting the underlying
neurovascular structures. The lead from the ipsilateral
electrode was advanced through the tunnel to the IPG
pocket leaving excess lead body in the cervical incision
to avoid tractionon the electrode arterial interface.Next
a tunnel was created between the two cervical incisions
just deep to the SCM crossing the neck at the lowest
point possible while avoiding injury to the thyroid
andany superficial vessels. The leadbody from the con-
tralateral electrode system was advanced through the
tunnel to the cervical incision ipsilateral to the IPG
pocket and then through the tunnel to the IPG pocket.
The lead bodies were repositioned within the tunnels
with loops in each incision providing strain relief thus
avoiding traction on the electrode-arterial interface.
The leads were then connected to the IPG. In Fig. 1,
the bilateral positioning of the CSL and location of the
IPG is given schematically together with an X-Ray
where the typical location of both CSLs can be seen.
The unit was again interrogated to confirm the ade-
quacy of the electrical connections. The hemodynamicresponse to a bilateral acute stimulation test was used
to confirm appropriate function if the anesthetic agents
used during the final phase of the procedure do not
blunt the baroreflex. The IPG was then turned off. The
IPG was sutured in place with permanent suture (3-O
Prolene) and the IPG pocket and cervical incisions
closed in layers with absorbable sutures.
Safety analysis
The safety analysis describes and analyses periopera-
tive procedure- and device-related adverse events as
reported by the investigators. All adverse events are
also reviewed by an independent adverse events
committee. The perioperative period includes the
time during which the implant procedure is being
conducted and the 30 day period following the
procedure.
Fig. 1. Postition of Carotid Sinus Leads and Impulse
Generator. A: Schematic presentation of positions of
bilateral perivascular carotid sinus stimulation electrodes
and the impulse generator. B: Postoperative radiograph of
a patient after implantation of the BHT device.Eur J Vasc Endovasc Surg Vol 33, April 2007
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Summary statistics (mean, standard deviation, mini-
mum and maximum for continuous variables and fre-
quency for categorical) were computed for baseline
and follow-up variables of interest. The maximal
response during dose response testing is calculated
as the largest difference between the baseline measure
at 0 volts and the measures obtained at 1e6 volts. The
mean maximal change in blood pressure and heart
rate during dose response testing is given along
with the standard deviation and confidence limits.
P-values for tests of significant maximal reductions
in blood pressure and heart rate during dose response
testing are by the t-Test for the mean change differing
from zero. Ninty-five percent confidence intervals are
provided to assist in determining the clinical signifi-
cance of the differences. A repeated measure ANOVA
was used to model the changes in blood pressure
and heart rate for increasing doses and across visits.
Unless otherwise specified, data are expressed as
mean standard deviation.
Results
Seventeen patients were enrolled between June 2004
and December 2005, all with severe hypertension de-
spite a multi-drug therapy with a mean of >5 con-
comitant antihypertensive drugs (see Table 3 for
their characteristics at entry). Implant procedures
were successfully completed in all patients within
an average of 202 43 minutes including 121 87
minutes used for determining and testing the optimal
location for CSL placement. The first acute tests, per-
formed in the awake state were conducted on postop-
erative day 1e3, prior to discharge from the hospital.
At this time, these tests gave significant (all:
p 0.0001) maximal reductions of systolic and dia-
stolic blood pressure and heart rate from
177 29 mmHg, 99 16 mmHg and 80 15 BPM at
baseline, to 141 34 mmHg, 78 21 mmHg and
68 14 BPM, respectively, which were observed at
a mean amplitude of 4.6 1.7 V. Mean maximal
changes, with standard deviations and 95% confi-
dence limits for systolic pressure, diastolic pressure
and heart rate are 28 22 (17, 39), 16 11 (10, 22)
and 8 4 (6, 11).
These tests, repeated monthly, showed consistent
acute dose-dependent reductions in SBP, DBP and
HR in that the degree of hemodynamic change was
directly related to the amplitude(voltage) of stimula-
tion. In Fig. 2 the results for the 1-month follow-up
(the formal baseline of the study) and 4 months followEur J Vasc Endovasc Surg Vol 33, April 2007up in the cohort completing 3 months of baroreflex
activation therapy (N¼ 16) are presented. Data for
Blood Pressure and Heart Rate during the testing at
both time points are given in Table 4. At both time
points the relationship between amplitude of stimu-
lation and hemodynamic response remained highly
linear while the control measurements (0 V) before
testing were lower at 4 months when compared to
the 1 month assessments. These lower control values
after 3 months of therapy with the device turned off
briefly (10e30 minutes) are related to the therapeutic
effect of BHT which has been previously reported
for a subset of these patients.25 A repeated measures
ANOVA analysis of blood pressure and heart rate
readings during testing across voltage steps tested
(0 volts to 6 volts) and visit (1 and 4 months) demon-
strated significant differences across doses (p< 0.0001
for each) and by visit (p¼ 0.003 for SBP, p¼ 0.0001 for
DBP and p< 0.0001 for HR).
Table 3. Patient Characteristics at Entry
Characteristic Mean SD
Gender (m/f) 8 m, 9 f
Age (years) 52.3 8.6 (33e67)
Height (cm) 170.9 10.4
Weight (kg) 91.9 25.0
BMI (kg/m2) 31.0 6.2
Office Cuff Blood Pressure and Pulse Rate
Systolic Blood Pressure (mmHg) 189.6 27.5
Diastolic Blood Pressure (mmHg) 110.7 15.3
Pulse Rate (BPM) 75.2 12.6
Number of Antihypertensive Drugs in
Combination
5.2 1.8
Fig. 2. Systolic Blood Pressure during Electrical Baroreflex
Activation System Tests. With bilateral activation, the ampli-
tude of the IPG (V¼Voltage) is increased in steps of 1 V
from 0 V (Baseline) to 6 V, each for 5 minutes. Mean systolic
blood pressure at each step is given for the test results in
16 patients. The 1-Month follow-up tests (open symbols)
were performed prior to the initiation of chronic therapy.
At the 4-Month follow-up test (closed symbols), the device
was turned off for 5 to 30 minutes before any acute testing
was started.
419An Implantable Carotid Sinus Baroreflex Activating SystemTable 4. Blood Pressure and Heart Rate during 1 and 4 Month System Tests
Parameter and Time Point Baroreflex Activation IPG Stimulation Amplitude (V)
0 1 2 3 4 5 6
SBP (mmHg)
1-Month 184 28 180 29 176 30 167 32 160 36 153 31 144 36
4-Month 165 21 164 21 163 27 160 23 155 27 147 30 143 30
DBP (mmHg)
1-Month 105 17 104 18 105 17 98 21 94 22 92 21 84 24
4-Month 95 17 94 16 93 17 92 15 89 17 84 17 81 17
HR (BPM)
1-Month 80 14 78 14 77 15 74 14 72 14 71 15 68 14
4-Month 68 11 67 10 68 11 65 11 65 11 64 12 62 12The implantation procedure was generally well tol-
erated. No unexpected serious procedure- or device
related adverse events or perioperative deaths were
reported. In the perioperative period, there were 38
procedure related adverse events reported in 17 pa-
tients, 2 system related events in 2 patients and one
event determined to be related to both the procedure
and system. Table 5 summarizes the assessment of
perioperative adverse events, which were related to
the procedure and/or the device. Of these events,
3 were classified as serious adverse events: 1. Infec-
tion, which led to the complete surgical removal of
the device in one patient. The IPG pocket was infected
with an spreading infection along the leads to the
neck incision at both side. High fever and serious
pain with redness, necessitated surgical reinterven-
tion and explantation of the system. 2. Procedure-
related hypoglossal nerve injury with symptoms of
hoarsiness and eating disturbances which improved
during follow up. In this patient the electrodes had
to be placed high on the carotid bifurcation which
Table 5. Perioperative Device and/or Procedure Related Adverse
Events
Adverse Event Device
Related
Procedure
Related
N
Events
N
Patients
with
event
Infection* 0 1 1 1
Hypoglossal Nerve
Injury
0 1 1 1
Intraoperative
Bradycardia
2 1 2 2
Pain 1 6 7 5
Wound
Complication
0 3 3 3
Extravascular
Tissue
Stimulation
0 1 1 1
Anaesthesia
Complications
0 2 2 2
Injury to local tissue 1 1 1
Other 22 23 16
Total 3 38 41 17
* During follow up, the complete device was surgically removed.resulted in an accidentally injury to the nerve, that
was sutured immediatedly with fine sutures (poly-
propylene 7x0), and 3. one case of intraoperative
bradycardia (to 20 beats/min), which recovered spon-
tanuously without any sustained effect. System and
procedure- related bradycardia has occurred during
system testing when brief periods of stimulation are
applied to determine and/or confirm the effects of
electrode positioning. Such episodes are expected
and related to the mechanism of baroreflex activation
and end within seconds by turning off the device.
Discussion
The results of acute dose response testing observed
during postoperative activation of this implanted de-
vice confirm that the regulation of blood pressure and
heart rate, by the central nervous system, is strongly
influenced by input from the carotid baroreceptor
pathways in patients with hypertension that is refrac-
tory to multi-drug therapy. Furthermore these reduc-
tions in blood pressure were consistently achieved
throughout the first three months of active therapy.
Finally these results suggest that the Rheos system
can be implanted safely in this group of patients
with significant cardiovascular risk factors.
Patients were only included in this study when that
fulfilled to strict inclusion criteria like the height of the
bloodpressure, number of antihypertensive medica-
tions and local factors at the carotid bifurcation site,
as determined by duplex scanning. This means that
any carotid artery stenosis> 50% was an exclusion cri-
teria. In this respect one may wonder, whether the risk
on future significant (symptomatic) carotid artery ste-
nosis may play a role in the decision to treat hyperten-
sive patients with the Rheos system. To date this
question remains unanswered and long-term follow
up probably will give insight into this issue, with
emphasis on the risk of carotid endarteriectomy in
these patients.Eur J Vasc Endovasc Surg Vol 33, April 2007
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the reduction in BP occurs in a dose dependent
manner, although in these tests only the amplitude
of stimulation was adjusted. These observations are
consistent with the findings of Schmidli et al. in
a group of patients undergoing carotid artery surgery
who underwent short term unilateral electrical stimu-
lation of the carotid sinus wall.24
At four months as compared to the one month data
there are some differences, which require discussion
and further study. The baseline blood pressure is sig-
nificantly lower, even though the device was turned
off for 5e30 minutes, at the 4-month time point:
165 21 mmHg vs. 184 28 mmHg at the 1-month
time point. This chronic blood pressure lowering ef-
fect of baroreflex activation therapy has been previ-
ously reported in a smaller cohort of these patients
by de Leeuw and colleagues.25 and is demonstrated
again in our data. Thus, effects of chronic baroreflex
activation therapy appear to be maintained in part
during this brief time that the therapy was inactive.
The lack of a rebound to baseline or greater blood
pressures is encouraging from a safety perspective
for BHT, but does confound our ability to easily inter-
pret the test findings. The second observation is that
of an apparent threshold effect at the 4-month time
point. This may reflect the development and organiza-
tion of scar tissue within the surgical field. This obser-
vation will require data from longer follow-up and
ongoing animal studies before a comprehensive
explanation can be provided.
Since we observed a qualitatively reproducible lin-
ear relationship between the hemodynamic response
to BHT and the voltage of stimulation used for BHT,
these acute tests may be considered ‘‘dose response’’
tests of BHT. The electrical parameters chosen for
the acute dose response tests used a stepwise increase
voltage with a constant frequency of 100 Hz and im-
pulse width of 0.48 ms. Voltage increases are thought
to increase the recruitment of afferent baroreceptor
fibers which elicits a spatial summation at the brain-
stem neuronal network involved in the processing of
the carotid baroreflex.27,28 A high stimulation fre-
quency is expected to minimize additional confound-
ing influences of potential differences in transmission
properties of the afferent neuronal fibers.29,30
The observations in this study, while new, are not
unexpected given previous work using carotid sinus
nerve stimulation. These studies conducted in the
1960s and 1970s evaluated the role of therapeutic
modulation of the carotid baroreflex in the treatment
of refractory hypertension and angina.11e17 The cur-
rent system is novel in that it uses perivascular elec-
trodes to activate the baroreflex. The current systemEur J Vasc Endovasc Surg Vol 33, April 2007addresses many of the challenges of the earlier de-
vices. Extraneous nerve and muscle stimulation and
pain resulting from current spread have been largely
solved with modern electrode technologies. The tech-
nique of placement of the electrode on the carotid si-
nus reduces the possibility of damage to the carotid
sinus nerves and allows the use of established tech-
niques employed in the treatment of atherosclerosis
of the carotid bifurcation. Finally, advances in im-
plantable medical devices allow the system to reliably
deliver stable and controlled therapy that can be cus-
tomized for each patient.
The long term SBP reduction of more than
20 mmHg observed even with the device turned off
briefly before the 3-month dose response testing is
impressive and exceeds the blood pressure lowering
effects demonstrated in a recent trial of a new
antihypertensive agent in patients with refractory
hypertension.31
A second similar study is underway in the USA.32
At the time of this report, 39 patients have been en-
rolled worldwide in both studies. The available
worldwide safety data from 39 implant procedures
corroborate our findings. With regard to procedure
and device related adverse events, the perioperative
infection which occurred in one of our patients was
treated with complete removal of the system and is
unfortunately an expected event seen with the im-
plantation of ICDs33 and other similar implantable
medical devices. Taking the worldwide experience
with the RHEOS device for BHT into account,
2 such infections have occurred (one in addition to
our observation in the US trial) which is within the ex-
pected rate of device-related infections and infection-
related explants.33e36
In conclusion, the preliminary data from our cohort
of 17 patients suggest that the Rheos implant proce-
dure can be performed with reasonably safety. How-
ever, we did saw serious complications in a minority
of patients. This combined with the sustained hemo-
dynamic response demonstrated for up to 4 months
postoperatively, still support further clinical develop-
ment of baroreflex activation as a new concept to treat
resistant hypertension. Such a concept is in line with
the treatment goal of sympathetic deactivation as re-
viewed recently by Grassi.37 Long-term therapeutic
results of this ongoing safety and efficacy trial are
needed as the basis for a multi-center, controlled trial
of the device for this indication.
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